U.S. Markets closed
  • S&P Futures

    4,269.00
    -12.00 (-0.28%)
     
  • Dow Futures

    33,631.00
    -87.00 (-0.26%)
     
  • Nasdaq Futures

    13,538.75
    -39.00 (-0.29%)
     
  • Russell 2000 Futures

    2,009.90
    -7.00 (-0.35%)
     
  • Crude Oil

    91.39
    -0.70 (-0.76%)
     
  • Gold

    1,811.50
    -4.00 (-0.22%)
     
  • Silver

    20.70
    +0.00 (+0.01%)
     
  • EUR/USD

    1.0250
    -0.0007 (-0.0718%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • Vix

    19.53
    -0.67 (-3.32%)
     
  • GBP/USD

    1.2115
    -0.0023 (-0.1914%)
     
  • USD/JPY

    133.2450
    -0.2350 (-0.1761%)
     
  • BTC-USD

    24,760.33
    +197.92 (+0.81%)
     
  • CMC Crypto 200

    590.86
    +19.58 (+3.43%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,851.26
    +304.28 (+1.07%)
     

Novavax is part of the FDA’s COVID-19 booster debate, but its vaccine still hasn’t been authorized

·3 min read
Novavax is part of the FDA’s COVID-19 booster debate, but its vaccine still hasn’t been authorized
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The experimental shot played a front-and-center role during this week’s debate about how best to update the COVID-19 vaccines to better protect against omicron.